Royalty Pharma PLC RPRX

US Pharmaceuticals

$68.49 ▼ -0.41% ($-0.28)

Open $68.48

Prev Close $68.77

Day Range $68.47 – $68.49

52W Range $37.31 – $69.77

Market Cap $38.79B

P/E (TTM) 58.84

Beta 0.37

Div Yield 2.96%

EPS (TTM) $1.21

📋 Company Profile

Industry	Pharmaceuticals
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2020-06-16
Shares Out.	575,000,000
Website	royaltypharma.com/ ↗
Phone	12128830200
Employees	100
Revenue	$690.1M
Gross Profit	$690.1M
Net Income	$266.6M
Free Cash Flow	$2.96B
Total Assets	$19.46B
Total Liabilities	$9.67B
Equity	$9.80B

About Royalty Pharma PLC

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Royalty Pharma PLC is a publicly traded company under the ticker symbol RPRX on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.